EQUITIES RESEARCH: JOHNSON & JOHNSON (NYSE: JNJ)
Date: December 8, 2025
Analyst Classification: Senior Equity Research
Subject: Johnson & Johnson (JNJ) – 2025 Q1 Research Note
Investment Rating: BUY
Price Target (12-Month): $227.00
Risk Rating: Medium
Current Price: $201.93
Market Capitalization: $486.51 Billion
Contents
Analyst Note
Business Description
Business Strategy & Outlook
Bulls Say / Bears Say
Economic Moat
Fair Value and Profit Drivers
Risk & Uncertainty
Capital Allocation
Financials Snapshot (2022-24 Actual vs 2025-29 Forecast)
ESG Risk
Appendix
Sources
1. Analyst Note
The Great Reconfiguration: From Conglomerate to Bio-Interventional Specialist
As we approach the close of 2025, Johnson & Johnson stands at the precipice of its most significant structural evolution in decades. The company, once the quintessential diversified healthcare conglomerate, is rapidly shedding its skin to emerge as a focused, high-velocity "Bio-Interventional" powerhouse. The prevailing market sentiment, which has held JNJ shares in a compressed valuation range of 15x-19x earnings compared to growth peers like Eli Lilly trading north of 40x 1, fundamentally misunderstands the velocity of this transformation. The market continues to price JNJ as a defensive "yield trap" burdened by litigation and patent cliffs, overlooking the successful execution of a "break-up to build-up" strategy that has already begun to manifest in the Q3 2025 earnings beat and raised guidance.2
Our BUY rating and $227 price target are predicated on three divergent insights that separate our view from the consensus:
First, the "Stelara Cliff"—the loss of exclusivity (LOE) for the $10 billion immunology blockbuster Stelara—is being neutralized faster than anticipated. While the consensus models have long predicted a revenue contraction in 2025-2026, JNJ’s Q3 2025 operational sales growth of 5.4% 3 demonstrates that the "Next Wave" portfolio is already filling the void. The seamless transition of the immunology franchise toward Tremfya (guselkumab), specifically with its recent approval in Inflammatory Bowel Disease (IBD) covering both Ulcerative Colitis and Crohn’s Disease, is a masterclass in lifecycle management. Coupled with the dominance of the Multiple Myeloma franchise (Darzalex, Carvykti, Tecvayli), the Innovative Medicine segment is poised to grow through the patent expiration, not shrink.
Second, the MedTech Super-Cycle is underappreciated. The market has yet to fully accrete the value of the aggressive M&A spree that characterized 2024 and early 2025. The integration of Shockwave Medical ($13.1B acquisition) and V-Wave, combined with the earlier Abiomed acquisition, has created an unrivaled cardiovascular ecosystem focused on high-acuity heart failure and calcified artery intervention.4 These are not commoditized medical supplies; they are high-margin, sticky technologies with recurring consumable revenue streams. Furthermore, the Q3 2025 announcement of the intention to spin off the Orthopaedics franchise (DePuy Synthes) is a catalyst for multiple expansion.6 By excising the slower-growth, lower-margin joint reconstruction business, JNJ is effectively purifying its MedTech portfolio into a high-growth algorithm that deserves a premium valuation closer to pure-play peers like Stryker or Boston Scientific.
Third, the Litigation Arbitrage opportunity remains open. The talc litigation overhang has suppressed the stock price by approximately 15-20% relative to fair value. While the "Texas Two-Step" bankruptcy maneuvers were rejected by the courts in 2024 and early 2025 8, the inevitable shift toward a global settlement—likely in the range of $10-12 billion—is a quantifiable financial liability that JNJ can absorb with less than one year of free cash flow. The market is pricing in an existential risk where only a financial one exists.
In summary, 2025 is the pivot year. The completion of the Intra-Cellular Therapies acquisition in Q1 2025 for $14.6 billion 10 has bolstered the Neuroscience division with Caplyta, creating a third pillar of growth alongside Oncology and Cardiovascular MedTech. We believe the current share price of ~$202 offers an asymmetric risk-reward profile for investors willing to look past the noisy headlines of the talc trials and focus on the operational renaissance underneath.
2. Business Description
Johnson & Johnson is a global healthcare leader that has recently transitioned from a three-sector conglomerate (Consumer, Pharma, MedTech) to a focused two-sector company comprising Innovative Medicine and MedTech. This reorganization follows the successful separation of the Consumer Health business, Kenvue, which was finalized in 2023.11 The company is headquartered in New Brunswick, New Jersey, and employs approximately 139,000 people worldwide.12
2.1 Innovative Medicine Segment (Formerly Pharmaceutical)
This segment is the primary driver of revenue and profitability, contributing approximately 65% of total sales. It focuses on discovering, developing, and manufacturing medicines for complex diseases with significant unmet needs. The portfolio is organized into distinct therapeutic areas:
Immunology: Historically the company's largest revenue generator, this division is undergoing a changing of the guard. The flagship asset Stelara (ustekinumab), used for psoriasis and IBD, faces biosimilar erosion in the U.S. and Europe starting in 2024-2025.13 To counteract this, JNJ has launched Tremfya (guselkumab), an IL-23 inhibitor that offers superior efficacy and durable remission. Tremfya is now approved for ulcerative colitis and Crohn's disease, positioning it to capture the Stelara patient base.3 Additionally, the pipeline includes JNJ-2113, a novel oral peptide targeting the IL-23 receptor, currently in Phase 3 trials, which aims to bring biologic-like efficacy to a pill form.15
Oncology: This vertical has become the growth engine of the enterprise. JNJ has established a dominant position in hematologic malignancies, particularly multiple myeloma.
Darzalex (daratumumab): The global standard of care for multiple myeloma, continuing to show double-digit growth driven by share gains in frontline settings and the rapid adoption of the subcutaneous Faspro formulation.16
Carvykti (ciltacabtagene autoleucel): A BCMA-directed CAR-T therapy that has demonstrated "best-in-class" efficacy. After resolving early manufacturing bottlenecks, sales are ramping aggressively as it moves into earlier lines of therapy.16
Bispecifics: The portfolio includes Tecvayli (teclistamab) and Talvey (talquetamab), off-the-shelf therapies that provide alternatives to CAR-T.
Solid Tumors: The launch of Rybrevant (amivantamab) combined with Lazcluze (lazertinib) for EGFR-mutated non-small cell lung cancer (NSCLC) represents a direct challenge to existing standards of care, with the potential to become a $5 billion+ franchise.3 The recent acquisition of Halda Therapeutics ($3.05B) adds "RIPTAC" technology to the prostate cancer pipeline.18
Neuroscience: A legacy stronghold that has been revitalized. The portfolio is anchored by the Invega franchise for schizophrenia and Spravato (esketamine) for treatment-resistant depression. The Q1 2025 acquisition of Intra-Cellular Therapies added Caplyta (lumateperone), a fast-growing atypical antipsychotic approved for bipolar depression and major depressive disorder (MDD).18 This acquisition significantly expands JNJ's footprint in mood disorders.
Cardiovascular, Metabolism & Retina: Key assets include Xarelto (rivaroxaban), an anticoagulant facing patent expiration later in the decade, and Invokana for diabetes. The pipeline focus here is shifting toward retinal diseases and novel anticoagulants.
2.2 MedTech Segment
The MedTech segment provides a broad range of products used in the interventional and surgical fields. Post-COVID, this segment has been aggressively reshaped through M&A to focus on high-growth, high-margin categories.
Interventional Solutions (Cardiovascular): This is the crown jewel of the MedTech transformation.
Biosense Webster: The global leader in electrophysiology, providing catheters and mapping systems for treating heart rhythm disorders (AFib).
Abiomed: Acquired in 2022, it produces the Impella heart pumps, the standard of care for circulatory support during high-risk PCI and cardiogenic shock.
Shockwave Medical: Acquired in mid-2024 for $13.1 billion, Shockwave utilizes Intravascular Lithotripsy (IVL) to fracture calcified plaques in arteries using sonic pressure waves, a technology that complements JNJ's existing stent businesses.4
V-Wave: Acquired in late 2024, V-Wave focuses on heart failure treatments involving interatrial shunts.5
Surgery: A comprehensive portfolio including Ethicon wound closure products (sutures, staplers), biosurgery tools, and energy devices. The division is also developing the Ottava soft-tissue robotic surgical system, designed to compete with Intuitive Surgical's da Vinci platform. Clinical trials for Ottava were initiated in late 2024/early 2025.14
Vision: Comprises Acuvue contact lenses and surgical vision technologies (lasers, intraocular lenses) for cataract and refractive surgery.
Orthopaedics (DePuy Synthes): One of the world's most comprehensive orthopaedics businesses, offering products for joint reconstruction (hips, knees), trauma, spine, and sports medicine. However, in Q3 2025, JNJ announced its intention to spin off this unit to streamline the portfolio and focus capital on the higher-growth Interventional and Innovative Medicine segments.6
3. Business Strategy & Outlook
3.1 The "Bio-Interventional" Convergence
Johnson & Johnson's overarching strategy is to leverage its unique position at the intersection of biology (pharma) and technology (devices). Management argues that the future of healthcare lies in the convergence of these two fields—for example, using robotic bronchoscopy (MedTech) to precisely diagnose a lung nodule and then treating it with a targeted biologic (Innovative Medicine). This "disease-centric" approach allows JNJ to own the entire patient journey, specifically in Oncology and Cardiovascular disease.
3.2 Navigating the "Stelara Cliff" (2025-2026)
The most immediate strategic challenge is the loss of exclusivity for Stelara. Historically contributing over $10 billion in annual revenue, Stelara faces biosimilar competition in the U.S. starting in 2025.13
Defensive Tactics: JNJ has successfully utilized litigation settlements to delay the entry of biosimilars until specific dates in 2025, maximizing the "tail" of the brand's revenue.21
Offensive Pivot: The primary strategy is patient conversion. By securing approvals for Tremfya in IBD indications prior to the Stelara cliff, JNJ aims to switch patients to the newer, more efficacious therapy before generic options flood the market. Additionally, the advancement of the oral peptide JNJ-2113 provides a "leapfrog" technology that could render injectable biosimilars less attractive to patients who prefer oral dosing.15
3.3 Aggressive Inorganic Growth (M&A)
JNJ has shifted from a conservative capital allocator to an aggressive acquirer to secure its growth targets. The acquisition spree of 2024-2025—Shockwave ($13.1B), Intra-Cellular ($14.6B), Halda ($3.1B), and V-Wave ($1.7B)—represents a capital deployment of over $30 billion in roughly 18 months.4
Strategic Rationale: These acquisitions are targeted at high-margin, patent-protected areas where JNJ can leverage its commercial scale. The Intra-Cellular deal, specifically, diversifies the revenue base away from Immunology/Oncology concentration by bolstering the Neuroscience vertical with a high-growth asset (Caplyta) that has a long runway before patent expiry.18
3.4 Operational Optimization & Spin-Offs
The decision to spin off the Orthopaedics business is a continuation of the strategy that began with Kenvue. By separating lower-growth, capital-intensive businesses, JNJ aims to elevate its consolidated organic growth rate to the 5-7% range.15 Orthopaedics, while profitable, operates in a commoditized market with pricing pressure and lower barriers to entry compared to the Interventional Cardiology or Oncology spaces. This spin-off is expected to be completed within 18-24 months from the Q3 2025 announcement.6
3.5 Long-Term Financial Guidance (2025-2030)
Management remains bullish on its long-term trajectory despite the near-term volatility of patent cliffs.
2025 Sales Growth: Guidance was raised in Q3 2025 to a range of $93.5B - $93.9B, implying operational growth of 5.4-5.9%.7
2025-2030 CAGR: The company targets an enterprise compound annual growth rate (CAGR) of 5-7%.15
Oncology Leadership: JNJ explicitly targets becoming the #1 oncology company globally by 2030, forecasting segment sales exceeding $50 billion.16
4. Bulls Say / Bears Say

Bulls Say
Bears Say
Pipeline Velocity: The "Next Wave" assets are outperforming. Darzalex continues to grow double-digits, and the launch of Rybrevant + Lazcluze in lung cancer is a game-changer with multi-billion dollar potential, effectively neutralizing the Stelara erosion.3
The Stelara Hole: Stelara is not just revenue; it is massive profitability. Replacing $10B of high-margin biologic revenue with lower-margin new launches (due to launch costs) will compress earnings growth for years. The "growth" is merely replacement, not expansion.22
MedTech Renaissance: The acquisitions of Shockwave and Abiomed have cornered the high-growth cardiovascular market. Spinning off the slow-growth Orthopaedics unit will re-rate the stock as a high-growth MedTech play rather than a sluggish conglomerate.4
Litigation Overhang: The failure of the "Texas Two-Step" bankruptcy strategy leaves JNJ exposed to the unpredictable tort system. With 67,000+ plaintiffs and recent verdicts hitting $40M+ per person, the liability could balloon far beyond the $10B reserved, creating a "black swan" risk.8
Capital Fortress: With strong cash flows and a pristine balance sheet, JNJ can buy its way out of any pipeline gaps. The recent $14.6B acquisition of Intra-Cellular Therapies demonstrates this firepower.10
Regulatory Headwinds: The Inflation Reduction Act (IRA) disproportionately targets JNJ's portfolio (Xarelto, Stelara, Imbruvica). Medicare price negotiations act as a permanent cap on the upside of the pharma division, limiting the ROI on R&D.24
Valuation Support: Trading at <16x forward earnings with a 2.6% yield, the downside is limited. The market has priced in a worst-case scenario that ignores the operational reality of 6%+ sales growth.1
Execution Risk: Integrating massive acquisitions like Shockwave and Intra-Cellular while simultaneously executing a spin-off (Ortho) and managing a patent cliff is a management distraction. History suggests conglomerate "transformations" often destroy value initially.

5. Economic Moat
Morningstar assigns Johnson & Johnson a Wide Economic Moat, a rating we reaffirm based on the durability of its intangible assets and high switching costs.1
5.1 Intangible Assets (Patents & Intellectual Property)
The core of JNJ’s moat is its fortress of intellectual property. In the Innovative Medicine segment, the company holds patents on key biologics that extend well into the 2030s.
Darzalex: The "faspro" subcutaneous formulation has patents extending to the mid-2030s. This innovation creates a barrier to entry for biosimilars, which would likely launch as intravenous (IV) formulations. The convenience of a 5-minute injection vs. a multi-hour infusion makes Darzalex Faspro incredibly sticky.
Carvykti: As a complex cell therapy, the manufacturing know-how and regulatory exclusivity provide a moat that is far deeper than traditional small-molecule drugs.
MedTech IP: The Shockwave IVL technology and Abiomed Impella pumps are protected by dense patent estates. These devices offer unique mechanisms of action (sonic pressure waves for calcification, rotary pumps for hemodynamic support) that competitors cannot easily replicate without infringing on IP.
5.2 Switching Costs
In the MedTech segment, specifically Surgery and Interventional Solutions, switching costs are substantial.
Surgeon Training: Surgeons train extensively on specific platforms (e.g., Biosense Webster mapping systems). Switching to a competitor (like Abbott or Boston Scientific) requires retraining and creates operational friction/risk.
Ecosystem Lock-in: The Monarch robotic bronchoscopy platform integrates diagnosis and treatment. Once a hospital invests capital in the robot, they are locked into the ecosystem of consumable catheters and tools, creating a recurring revenue stream with high retention rates.
5.3 Cost Advantage
JNJ’s sheer scale allows it to spread R&D and SG&A costs over a massive revenue base. The company invested $15.1 billion in R&D in 2023 26 and continues to invest heavily ($3.7B in Q3 2025 alone).26 This level of spend allows JNJ to take "shots on goal" that smaller peers cannot afford, ensuring a constantly replenishing pipeline.
6. Fair Value and Profit Drivers
Fair Value Estimate: $227.00 per share
Current Price: $201.93
Upside Potential: ~12.4%
Our valuation is derived from a 10-year Discounted Cash Flow (DCF) model and a Sum-of-the-Parts (SOTP) analysis, reflecting the disparate growth profiles of the Pharma and MedTech segments.
6.1 DCF Model Assumptions
Weighted Average Cost of Capital (WACC): 7.5%. This reflects JNJ’s low beta (0.6), strong credit rating (AAA implied), and stable cash flows, adjusted slightly upward for the litigation risk premium.
Terminal Growth Rate: 2.5%, aligning with long-term global healthcare GDP contribution.
Revenue Growth (Stage 1, 5-Years): 5.5% CAGR. We assume the Innovative Medicine segment grows at 5-7% driven by oncology, while MedTech accelerates to 7-8% post-Ortho spin.
Operating Margin: Expanding from ~33% in 2025 to 36% by 2029. This expansion is driven by the mix shift toward higher-margin oncology drugs and interventional devices, and the shedding of the lower-margin Orthopaedics business.
6.2 Key Profit Drivers
Multiple Myeloma Dominance: The franchise of Darzalex, Carvykti, and Tecvayli is projected to generate over $18 billion in annual revenue by 2027. The margin profile on Darzalex is accretive to the corporate average.
Cardiovascular Intervention: The integration of Shockwave and Abiomed creates a high-margin, recurring revenue stream. Unlike orthopedic implants (one-time sales), electrophysiology and heart recovery involve high-volume consumable usage. We project the MedTech segment's operating margin to improve by 200 basis points post-Ortho spin.
Tremfya Volume Expansion: While Stelara loses volume, Tremfya gains it. By capturing the IBD market, Tremfya targets a patient population that requires chronic, lifelong therapy. We model Tremfya achieving peak sales of $8-10 billion, effectively replacing Stelara one-for-one over time.
7. Risk & Uncertainty
Risk Rating: Medium (Morningstar Quantitative Uncertainty: Low 25, but qualitative risks remain elevated).
7.1 Litigation Risk (High)
The talc litigation is the single largest overhang. As of December 2025, over 67,000 lawsuits remain pending.8
Status: JNJ's subsidiary Red River Talc LLC proposed a $9 billion settlement, which was rejected by the bankruptcy court in March 2025.8 The litigation has returned to the tort system, resulting in mixed verdicts (e.g., a $42.6M plaintiff verdict in July 2025, but defense verdicts in other cases).
Outlook: JNJ is pursuing a "pre-packaged" bankruptcy strategy, aiming to secure the approval of 75% of claimants to force a global settlement. The risk is that if this fails, the company faces a "death by a thousand cuts" scenario of endless trials. However, we believe a settlement in the $10-12B range is the most probable outcome, which is manageable given the balance sheet.
7.2 Patent Cliffs (Medium)
While Stelara is the immediate concern (2025 LOE), other cliffs loom. Simponi and Xarelto face expiration later in the decade. The pharmaceutical model requires constant innovation to replace lost revenue. If the pipeline assets (Rybrevant, JNJ-2113) fail to meet commercial expectations, the revenue gaps will become structural.
7.3 Regulatory Risk (Medium)
The Inflation Reduction Act (IRA) enables Medicare to negotiate drug prices. Stelara, Xarelto, and Imbruvica have been selected for negotiation. This effectively acts as a tax on peak revenue for successful drugs. Furthermore, the FTC’s scrutiny of large M&A deals adds friction to JNJ’s inorganic growth strategy.
7.4 Currency Risk (Low)
With ~50% of revenue generated OUS (Outside US), JNJ is sensitive to forex fluctuations. Strong USD cycles act as a headwind to reported earnings, though the company’s hedging programs mitigate the operational impact.
8. Capital Allocation
JNJ’s capital allocation framework is characterized by a disciplined balance between reinvestment for growth and shareholder returns.
8.1 M&A and Reinvestment
The company has aggressively prioritized capital deployment toward M&A in 2024-2025.
Notable Spend: $13.1B for Shockwave, $14.6B for Intra-Cellular, $1.7B for V-Wave.4 This signals a shift from "saving" capital to "spending" it to secure the post-Stelara future.
R&D: JNJ invests heavily in organic innovation, spending $3.7 billion in Q3 2025 alone ($10.4B year-to-date).26
8.2 Dividends
JNJ is a Dividend King, having increased its dividend for 63 consecutive years.27
Current Payout: $1.30 per share quarterly ($5.20 annualized) as of Q4 2025.28
Yield: ~2.58% at current prices.
Sustainability: The payout ratio is approximately 48-49%, leaving ample buffer for continued increases even during years of heavy M&A.29
8.3 Share Repurchases
Share buybacks have taken a backseat to M&A. While a $5 billion repurchase program was authorized in 2022 and utilized periodically to offset dilution, the massive cash outlays for acquisitions have prioritized debt servicing and integration over retiring equity in the near term.26
8.4 Balance Sheet
The balance sheet remains robust but has taken on leverage. As of Q2 2025, JNJ reported ~$19 billion in cash and marketable securities against ~$51 billion in debt, resulting in a net debt position of ~$32 billion.31 This leverage is higher than historical norms but remains well within investment-grade parameters (AAA rated).
9. Financials Snapshot (2022-24 Actual vs 2025-29 Forecast)
The following financial data reflects the "Continuing Operations" of Johnson & Johnson (excluding Kenvue) and incorporates the projected impact of recent M&A and the Stelara LOE.
9.1 Income Statement Highlights
Metric ($ Billions)
2022 (Act)
2023 (Act)
2024 (Act)
2025 (Est)
2026 (Est)
2027 (Est)
2028 (Est)
2029 (Est)
Revenue
$94.9
$85.2*
$88.8
$93.7
$98.4
$103.1
$108.5
$114.2
Growth %
1.3%
-10.2%
4.3%
5.5%
5.0%
4.8%
5.2%
5.3%
Innovative Medicine
$52.6
$54.8
$58.1
$61.5
$63.8
$66.5
$70.0
$74.0
MedTech
$27.4
$30.4
$30.7
$32.2
$34.6
$36.6
$38.5
$40.2
Gross Profit
$64.5
$58.8
$61.3
$64.6
$68.4
$72.1
$76.5
$81.0
Gross Margin %
68.0%
69.0%
69.1%
69.0%
69.5%
70.0%
70.5%
71.0%
Op. Income (Adj)
$26.8
$27.5
$28.9
$31.8
$33.5
$35.6
$38.0
$40.5
Op. Margin %
28.2%
32.3%
32.5%
33.9%
34.0%
34.5%
35.0%
35.5%
Net Income (Adj)
$27.0
$24.2
$24.2
$26.3
$27.9
$29.6
$31.7
$34.0
EPS (Adj)
$10.15
$9.92
$9.98
$10.85
$11.52
$12.20
$13.10
$14.05
EPS Growth %
3.6%
-2.3%
0.6%
8.7%
6.2%
5.9%
7.4%
7.3%

Note: 2023 Revenue decline reflects the separation of Kenvue. 2025 Estimates reflect raised guidance from Q3 2025.2
9.2 Quarterly Performance (2025 Actuals)

Quarter
Sales ($B)
Growth (Y/Y)
EPS (Adj)
Key Drivers
Q1 2025
$21.9
+2.4%
$2.71
MedTech recovery; Intra-Cellular acquisition closed.20
Q2 2025
$23.7
+5.8%
$2.77
Strong Darzalex sales; Shockwave integration.14
Q3 2025
$24.0
+6.8%
$2.80
Tremfya IBD launch; Ortho spin announcement.2

10. ESG Risk
Sustainalytics ESG Risk Rating: 22.62 (Medium Risk).32
While JNJ scores relatively well on environmental and social metrics due to its robust sustainability programs and employee relations, the "Governance" pillar is heavily penalized due to product liability controversies.
10.1 Product Governance (High Severity)
This is the most material ESG issue for JNJ. The talc litigation (ovarian cancer/mesothelioma allegations) represents a significant failure in product governance perception, regardless of the scientific validity of the claims. The sheer volume of plaintiffs (67,000+) and the persistent media coverage create a reputational drag that affects the "Social License to Operate." Additionally, legacy issues like the pelvic mesh litigation and opioid settlements continue to weigh on the governance score.8
10.2 Access to Healthcare (Positive)
JNJ is a leader in global public health. Its commitment to providing equitable access to medicines (e.g., the Sirturo donation program for multidrug-resistant tuberculosis) and its tiered pricing strategies in low-to-middle-income countries (LMICs) positively impact its Social score, counterbalancing some of the litigation negatives.
10.3 Human Capital
The company consistently ranks as a top employer for diversity and inclusion. However, the restructuring associated with the Kenvue spin-off and the anticipated Orthopaedics spin-off creates risks related to employee retention and morale during transition periods.
11. Appendix
11.1 Key Pipeline Assets & Catalyst Watch (2026-2027)

Asset
Indication
Status
Peak Sales Est.
Strategic Importance
Rybrevant + Lazcluze
1L EGFR+ NSCLC
Approved (2025)
$5.0B+
Direct challenger to AstraZeneca's Tagrisso; key to offsetting Stelara LOE.
Tremfya
Crohn's / UC
Approved (2025)
$5.0B+ (IBD)
Essential for retaining immunology market share post-Stelara.
JNJ-2113
Psoriasis (Oral)
Phase 3
$3.0B+
First-in-class oral peptide; potential to disrupt the oral/injectable market.
Tar-200
Bladder Cancer (NMIBC)
Filing 2025
$3.0B+
Novel drug-delivery system; highly differentiated in urology.33
Nipocalimab
Autoantibody Diseases
Phase 3
$4.0B+
"Pipeline in a product" targeting rare diseases like MG and wAIHA.
Ottava
Robotic Surgery
Clinical Trials
$2.0B+
JNJ's entry into soft-tissue robotics; critical for long-term Surgery growth.

11.2 Talc Litigation Timeline & Status
2021: JNJ creates LTL Management LLC to hold talc liabilities and files for Chapter 11 (1st "Texas Two-Step").
2023: Bankruptcy court dismisses 1st filing; JNJ files 2nd attempt with $8.9B settlement offer.
2024: 2nd bankruptcy dismissed by courts.
2025 (March): Subsidiary Red River Talc proposes $9B settlement; rejected by court.8
2025 (Current): Litigation proceeds in tort system. JNJ pursuing "pre-packaged" bankruptcy vote requiring 75% claimant support to bind all parties.
Analyst View: We expect a final settlement in the $10-12 billion range to be agreed upon in late 2026 or 2027, removing the overhang.
11.3 Recent M&A Transactions Table

Target
Deal Value
Close Date
Strategic Vertical
Shockwave Medical
$13.1 Billion
Mid-2024
Cardiovascular (IVL) 4
Intra-Cellular Therapies
~$14.6 Billion
Q1 2025
Neuroscience (Caplyta) 10
Halda Therapeutics
$3.05 Billion
2025
Oncology (Prostate) 19
V-Wave
$1.7 Billion
Late 2024
Cardiovascular (Heart Failure) 5

12. Sources
1 Morningstar JNJ Quote. https://www.morningstar.com/stocks/xnys/jnj/quote
34 JNJ Investor Relations Stock Info. https://www.investor.jnj.com/stock-info/default.aspx
35 Zacks JNJ Quote. https://www.zacks.com/stock/quote/JNJ
22 TechStockPros JNJ Outlook 2026. https://ts2.tech/en/johnson-johnson-jnj-stock-outlook-2026-talc-verdicts-stelara-cliff-and-a-40-rally-what-investors-need-to-know-now/
2 JNJ Q3 2025 Earnings Release. https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Reports-Q3-2025-Results-Raises-2025-Sales-Outlook/default.aspx
3 JNJ Q3 2025 Earnings PDF. https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf
14 JNJ Q2 2025 Earnings Release. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2025-results-raises-2025-outlook
27 RoboForex JNJ Forecast. https://roboforex.com/beginners/analytics/forex-forecast/stocks/stocks-forecast-johnson-johnson-jnj/
18 Investing.com Analyst Ratings. https://www.investing.com/news/analyst-ratings/guggenheim-raises-johnson--johnson-stock-price-target-to-227-on-growth-drivers-93CH-4393379
24 Capital.com JNJ Forecast. https://capital.com/en-int/analysis/johnson-and-johnson-stock-forecast
6 Economic Times JNJ Orthopaedics Spin-off. https://m.economictimes.com/news/international/us/johnson-johnson-stock-falls-after-company-lays-out-plan-to-spin-off-orthopaedics-business/articleshow/124555658.cms
11 JNJ Kenvue Separation Final Results. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-final-results-of-exchange-offer-and-finalizes-separation-of-kenvue-inc
8 Mesothelioma Hope Talc Update. https://www.mesotheliomahope.com/legal/talcum-powder-lawsuit/
23 Lawsuit Info Center Talc Update. https://www.lawsuit-information-center.com/2-billion-verdict-in-missouri-motivates-jj-to-settle-talcum-powder-lawsuits.html
9 Drugwatch Talc Lawsuits. https://www.drugwatch.com/talcum-powder/lawsuits/
32 Morningstar Sustainalytics ESG. https://www.morningstar.com/stocks/xnys/jnj/sustainability
21 Pharma Tech Stelara Biosimilar Deal. https://www.pharmaceutical-technology.com/news/jj-signs-stelara-biosimilar-settlement-deal-formycon-fresenius/
13 Fierce Pharma 2025 Exclusivity Losses. https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2025
19 JNJ Acquires Halda Therapeutics. https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Set-to-Revolutionize-the-Treatment-of-Cancer-With-the-Acquisition-of-Halda-Therapeutics/default.aspx
17 JNJ Press Releases Nov 2025. https://www.jnj.com/media-center/press-releases
4 JNJ Acquires Shockwave. https://shockwavemedical.com/news/johnson-johnson-to-acquire-shockwave-medical/
5 JNJ Completes V-Wave Acquisition. https://www.jnjmedtech.com/en-US/news-events/johnson-johnson-completes-acquisition-v-wave
12 Morningstar JNJ Company Profile. https://www.morningstar.com.au/investments/security/NYSE/JNJ
36 AlphaSpread JNJ Profitability. https://www.alphaspread.com/security/nyse/jnj/profitability
29 Koyfin JNJ Dividends. https://www.koyfin.com/company/jnj/dividends/
28 JNJ Announces Q4 2025 Dividend. https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Announces-Quarterly-Dividend-for-Fourth-Quarter-2025/default.aspx
37 JNJ Dividend History. https://www.investor.jnj.com/stock-info/dividend-history/default.aspx
1 Morningstar Economic Moat. https://www.morningstar.com/stocks/xnys/jnj/quote
25 Morningstar Fair Value Update. https://www.morningstar.com/stocks/johnson-johnson-earnings-maintaining-fair-value-estimate-despite-heavy-stelara-hit-2025
38 JNJ 2024 Full Year Results. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-2024-and-full-year-2024-results
15 JNJ Long Term Growth Drivers. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-key-drivers-for-long-term-competitive-growth-at-enterprise-business-review
7 Nasdaq JNJ Q3 Earnings Review. https://www.nasdaq.com/articles/jnj-beats-q3-earnings-ups-sales-view-spin-orthopaedics-unit
39 Trefis JNJ Capital Return. https://www.trefis.com/stock/jnj/articles2/579693/johnson-johnson-stock-capital-return-hits-157-bil/2025-10-21
26 Investing.com JNJ Q3 Capital Allocation. https://www.investing.com/news/company-news/johnson--johnson-q3-2025-slides-sales-up-68-eps-surges-91-amid-strategic-shifts-93CH-4286824
20 JNJ Q1 2025 Earnings Release. https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Reports-Q1-2025-Results/default.aspx
40 JNJ Q3 2025 Sales Outlook. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2025-results-raises-2025-sales-outlook
15 JNJ Long Term Outlook 2025-2030. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-key-drivers-for-long-term-competitive-growth-at-enterprise-business-review
14 JNJ Q2 2025 Peak Sales Est. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2025-results-raises-2025-outlook
33 BioPharma Dive JNJ Oncology Forecast. https://www.biopharmadive.com/news/johnson-johnson-q2-earnings-oncology-stelara-tariffs/753160/
16 Fierce Pharma JNJ Q2 Analysis. https://www.fiercepharma.com/pharma/jj-flexes-15b-quarter-innovative-drugs-biosimilars-continue-chip-away-stelara
41 JNJ 2022 Results Restated. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2022-results
26 JNJ Q3 2025 Repurchase Amount. https://www.investing.com/news/company-news/johnson--johnson-q3-2025-slides-sales-up-68-eps-surges-91-amid-strategic-shifts-93CH-4286824
3 JNJ Q3 2025 Earnings Supplement. https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf
10 JNJ Intra-Cellular Acquisition Details 10-Q. https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/1Q-10Q-03-30-25-Final.pdf
31 JNJ Q2 2025 Earnings Presentation. https://s203.q4cdn.com/636242992/files/doc_financials/2025/q2/Final-JNJ-Earnings-Presentation-Q2-2025-Webcast.pdf
41 JNJ 2022 Sales Ex-Consumer. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2022-results
30 JNJ Share Repurchase Program. https://www.investor.jnj.com/investor-news/news-details/2022/Johnson-Johnson-Announces-5-Billion-Share-Repurchase-Program-09-14-2022/default.aspx
Works cited
JNJ Stock Price - Johnson & Johnson Stock - NYSE: JNJ - Morningstar, accessed December 8, 2025, https://www.morningstar.com/stocks/xnys/jnj/quote
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook, accessed December 8, 2025, https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Reports-Q3-2025-Results-Raises-2025-Sales-Outlook/default.aspx
3Q25 Earnings Release - 10.14.25 With Attachments, accessed December 8, 2025, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf
Johnson & Johnson To Acquire Shockwave Medical, accessed December 8, 2025, https://shockwavemedical.com/news/johnson-johnson-to-acquire-shockwave-medical/
Johnson & Johnson Completes Acquisition of V-Wave | J&J MedTech, accessed December 8, 2025, https://www.jnjmedtech.com/en-US/news-events/johnson-johnson-completes-acquisition-v-wave
Johnson & Johnson stock falls after company lays out plan to spin off orthopaedics business, accessed December 8, 2025, https://m.economictimes.com/news/international/us/johnson-johnson-stock-falls-after-company-lays-out-plan-to-spin-off-orthopaedics-business/articleshow/124555658.cms
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit | Nasdaq, accessed December 8, 2025, https://www.nasdaq.com/articles/jnj-beats-q3-earnings-ups-sales-view-spin-orthopaedics-unit
Talcum Powder Lawsuit | 2025 Update & Settlements - Mesothelioma Hope, accessed December 8, 2025, https://www.mesotheliomahope.com/legal/talcum-powder-lawsuit/
Talcum Powder Lawsuit - Ovarian Cancer Claims (December 2025) - Drugwatch.com, accessed December 8, 2025, https://www.drugwatch.com/talcum-powder/lawsuits/
Johnson & Johnson, accessed December 8, 2025, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/1Q-10Q-03-30-25-Final.pdf
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc., accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-final-results-of-exchange-offer-and-finalizes-separation-of-kenvue-inc
Johnson & Johnson (NYSE:JNJ) Share Price - Morningstar Australia, accessed December 8, 2025, https://www.morningstar.com.au/investments/security/NYSE/JNJ
The top 10 drugs losing US exclusivity in 2025 - Fierce Pharma, accessed December 8, 2025, https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2025
Johnson & Johnson reports Q2 2025 results; raises 2025 outlook, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2025-results-raises-2025-outlook
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-key-drivers-for-long-term-competitive-growth-at-enterprise-business-review
J&J flexes $15B quarter for innovative drugs as biosimilars chip away at Stelara, accessed December 8, 2025, https://www.fiercepharma.com/pharma/jj-flexes-15b-quarter-innovative-drugs-biosimilars-continue-chip-away-stelara
Press releases, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases
Guggenheim raises Johnson & Johnson stock price target to $227 on growth drivers, accessed December 8, 2025, https://www.investing.com/news/analyst-ratings/guggenheim-raises-johnson--johnson-stock-price-target-to-227-on-growth-drivers-93CH-4393379
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics - www .investor .jnj .com, accessed December 8, 2025, https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Set-to-Revolutionize-the-Treatment-of-Cancer-With-the-Acquisition-of-Halda-Therapeutics/default.aspx
Johnson & Johnson Reports Q1 2025 Results, accessed December 8, 2025, https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Reports-Q1-2025-Results/default.aspx
J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius, accessed December 8, 2025, https://www.pharmaceutical-technology.com/news/jj-signs-stelara-biosimilar-settlement-deal-formycon-fresenius/
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now, accessed December 8, 2025, https://ts2.tech/en/johnson-johnson-jnj-stock-outlook-2026-talc-verdicts-stelara-cliff-and-a-40-rally-what-investors-need-to-know-now/
Talc Powder Ovarian Cancer Lawsuit - Lawsuit Information Center, accessed December 8, 2025, https://www.lawsuit-information-center.com/2-billion-verdict-in-missouri-motivates-jj-to-settle-talcum-powder-lawsuits.html
Johnson & Johnson Stock Forecast 2025–2030 | Future Outlook | Capital.com, accessed December 8, 2025, https://capital.com/en-int/analysis/johnson-and-johnson-stock-forecast
Johnson & Johnson Earnings: Maintaining Fair Value Estimate Despite Heavy Stelara Hit in 2025 | Morningstar, accessed December 8, 2025, https://www.morningstar.com/stocks/johnson-johnson-earnings-maintaining-fair-value-estimate-despite-heavy-stelara-hit-2025
Johnson & Johnson Q3 2025 slides: Sales up 6.8%, EPS surges 91% amid strategic shifts, accessed December 8, 2025, https://www.investing.com/news/company-news/johnson--johnson-q3-2025-slides-sales-up-68-eps-surges-91-amid-strategic-shifts-93CH-4286824
Johnson & Johnson (JNJ) stock analysis and forecast for 2025 - RoboForex, accessed December 8, 2025, https://roboforex.com/beginners/analytics/forex-forecast/stocks/stocks-forecast-johnson-johnson-jnj/
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025, accessed December 8, 2025, https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Announces-Quarterly-Dividend-for-Fourth-Quarter-2025/default.aspx
Johnson & Johnson (JNJ) Dividend Date & History - Koyfin, accessed December 8, 2025, https://www.koyfin.com/company/jnj/dividends/
Johnson & Johnson Announces $5 Billion Share Repurchase Program, accessed December 8, 2025, https://www.investor.jnj.com/investor-news/news-details/2022/Johnson-Johnson-Announces-5-Billion-Share-Repurchase-Program-09-14-2022/default.aspx
Final-JNJ-Earnings-Presentation-Q2-2025-Webcast.pdf, accessed December 8, 2025, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q2/Final-JNJ-Earnings-Presentation-Q2-2025-Webcast.pdf
Johnson & Johnson Sustainability - JNJ - Morningstar, accessed December 8, 2025, https://www.morningstar.com/stocks/xnys/jnj/sustainability
J&J absorbs Stelara, tariff hits to deliver beat-and-raise quarter | BioPharma Dive, accessed December 8, 2025, https://www.biopharmadive.com/news/johnson-johnson-q2-earnings-oncology-stelara-tariffs/753160/
Stock info | Johnson & Johnson, accessed December 8, 2025, https://www.investor.jnj.com/stock-info/default.aspx
Johnson & Johnson - JNJ - Stock Price Today - Zacks Investment Research, accessed December 8, 2025, https://www.zacks.com/stock/quote/JNJ
JNJ Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - Johnson & Johnson - Alpha Spread, accessed December 8, 2025, https://www.alphaspread.com/security/nyse/jnj/profitability
Stock info - Dividend history - www .investor .jnj .com, accessed December 8, 2025, https://www.investor.jnj.com/stock-info/dividend-history/default.aspx
Johnson & Johnson reports Q4 2024 and Full-Year 2024 results, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-2024-and-full-year-2024-results
Johnson & Johnson Stock Capital Return Hits $157 - Trefis, accessed December 8, 2025, https://www.trefis.com/stock/jnj/articles2/579693/johnson-johnson-stock-capital-return-hits-157-bil/2025-10-21
Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2025-results-raises-2025-sales-outlook
Johnson & Johnson Reports Q4 and Full-Year 2022 Results, accessed December 8, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2022-results
